Pharmaceutical

South Korean company Dong-A ST wins FDA approval for Stelara biosimilar

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

Oct 12, 2024 - 04:00
South Korean company Dong-A ST wins FDA approval for Stelara biosimilar
Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.
Read the original article

Tags:

Previous Article

Scholar Rock’s Phase 3 SMA Trial Achieves Success

Next Article

FDA AdCom votes in favour of Stealth’s Barth syndrome drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

J&J seeks label expansion for Tremfya in ulcerative colitis

J&J seeks label expansion for Tremfya in ulcerative col...

Mar 13, 2024

STAT+: A devastating skin condition could soon get its first medication, as the frontiers of gene therapy expand

STAT+: A devastating skin condition could soon get its ...

Apr 3, 2023

STAT+: Google will let health care customers test its generative AI model, ramping up rivalry with GPT-4

STAT+: Google will let health care customers test its g...

Apr 13, 2023